Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.68 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.68 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.68 |
| ▸ | MAPK10 | P53779 | 13/20 | 0.46 |
| ▸ | HRH4 | Q9H3N8 | 3/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 1/20 | 0.37 |
| ▸ | HTR2B | P41595 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6529885 | 0.88 | MAPK8 (0.78) | EGFRMAPK8MAPK9MAPK10HRH4 | |
| SCHEMBL6527523 | 0.86 | EGFR (0.81) | EGFRMAPK8MAPK9MAPK10HRH4 | |
| SCHEMBL6530859 | 0.84 | MAPK8 (0.75) | EGFRMAPK8MAPK9MAPK10HRH4 | |
| SCHEMBL6478238 | 0.82 | EGFR (0.97) | EGFRMAPK8MAPK9MAPK10HRH4 | |
| SCHEMBL6485328 | 0.81 | EGFR (1.00) | EGFRMAPK8MAPK9MAPK10HRH4 | |
| SCHEMBL6476578 | 0.80 | MAPK8 (0.71) | EGFRMAPK8MAPK9MAPK10HRH4 | |
| SCHEMBL6487771 | 0.80 | MAPK8 (0.66) | EGFRMAPK8MAPK9MAPK10HRH4 | |
| SCHEMBL6476674 | 0.79 | EGFR (0.81) | EGFRMAPK8MAPK9MAPK10HRH4 | |
| SCHEMBL6476588 | 0.79 | MAPK8 (0.65) | EGFRMAPK8MAPK9MAPK10HRH4 | |
| SCHEMBL6477634 | 0.79 | EGFR (0.93) | EGFRMAPK8MAPK9MAPK10HRH4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6891039-B2 | Imidazo [4,5-B] pyridine compounds and their pharmaceuticals use | NOVARTIS AG (CH) | 2005-05-10 | — | — | US | claimed |
| US-20040082604-A1 | Thiazole and imidazo (4,5-B) pyridine compounds and their pharmaceutical use | REVESZ LASZLO (CH) | 2004-04-29 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082604-A1 | Thiazole and imidazo (4,5-B) pyridine compounds and their pharmaceutical use | MAPK1, IRAK1, IRAK4 | EGFR 1067/4885MAPK8 42/4885MAPK9 43/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.